Slides
Page 1
1 Q1 FY27 Performance RPG Life Sciences Investors’ Presentation July 2026
Page 2
2 Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward- looking statements. The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company , its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly , from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty , express or implied, for the contents of this document including its accuracy , fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for , any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.
Page 3
3 RPG Group: Powered by Passion, Driven by Ethics RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India’s fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 5.2 Bn EPC major in infrastructure segments like T&D, Civil, Transportation, Oil & Gas, Renewables & Cables One of India’s leading tyre manufacturers Global technology consulting and IT services company Integrated pharma company in formulations and synthetic APIs Technology solutions company catering to energy and infrastructure One of India’s largest plantation companies producing tea, rubber, etc.
Page 4
4 RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Manufacturing Facilities – API and Formulations Leader in Immunosuppressants 9 Therapies represented by High Equity Brands 1445+ Employees 50+ Markets Presence Domestic Formulations (DF) Develop, manufacture and market branded formulations in India & Nepal International Formulations (IF) Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space APIs Develop, manufacture and sell high value synthetic APIs in the general therapeutic category Domestic Formulation s (DF) 65% Domestic Formulation s 66% International Formulations (IF) 18% Domestic Formulations (DF) 68% APIs 14%
Page 5
5 RPG Life Sciences: Strong Product Portfolio, T extbook brands; focus on chronic & specialty therapies Immunosuppressants Textbook Brands New Portfolio Azathioprine Spironolactone Diphenoxylate HCl Naproxen Haloperidol Azathioprine Cyclosporine Mycophenolate Mofetil Tacrolimus Specialty Chronic Trastuzumab Adalimumab Bevacizumab Rituximab Tofacitinib Teneligliptin DF Key Products Key Therapies Disopyramide Phosphate Vildagliptin Life Cycle Management (Existing Products) Dapagliflozin Denosumab Nephrology Rheumatology Oncology Pain Management Gastroenterology Neuropsychiatry Cardio- Diabeto Urology Legacy Portfolio Solifenacin Sacubitril+ Valsartan Ferric Carboxymaltose IF Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline and so on Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope and so on APIs Key Products Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole and so on
Page 6
6 Business Operations
Page 7
7 Quality – Centric Operations with Scalable Capabilities • Located in the industrial town of Ankleshwar in Gujarat, India; the Multipurpose plant with dedicated product lines for Oral Dosage forms including tablets, liquids, and powder. This manufacturing facility is equipped to handle products which require very low humidity during processing and caters to the regulated markets. The unit has a strong production capacity and caters to the Domestic and Emerging markets. Formulation - Ankleshwar , Gujarat • The API Manufacturing facility consists of three district units, each aligned to specific market requirements. MF2 operates as a dedicated immunosuppressant unit, while MF3 and MF4 are multipurpose facilities, collectively catering to regulated markets. API - Navi Mumbai, Maharashtra
Page 8
8 Intelligent Chilling Plant Manager • Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics IOT based AHU monitoring system • Operates Pumps & Chillers according to Operating Hours to maintain equal run time • Automatically change over Working pump to Standby if Pump fails during operation Power Management System • Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets always enabled Digital Retina Scanner • Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures • Access to only qualified professionals, Batch Management, Recipe Management, Audit logs Quality Functions e-QMS: Digital platform to track all 6 quality parameters e-DMS: Digital platform to manage manufacturing/quality documents e-LMS: Digital platform to track training sessions on CGMP Digital Initiatives: Manufacturing and Quality
Page 9
9 Strengthening Manufacturing & Capacity Enhancing capacity and capabilities to support scalable and future -ready growth Focusing on execution to drive growth & efficiency Driving improvement across cost, quality, growth & productivity 1 Multiple initiatives underway with defined KPIs and strong review mechanisms Driving Cost Efficiency Implementing cost optimization initiatives to improve productivity and operating margins Enhancing Quality & Compliance Strengthening quality systems and compliance to ensure consistent reliability Accelerating New Products & Innovation Investing in R&D and innovation to drive new launches and specialty expansion Leveraging Digital & Productivity Using digital initiatives to enhance execution, reach and overall productivity Expanding Global Presence Strengthening our footprint and partnerships to unlock opportunities in fast-growing global markets 2 3 4 5 6
Page 10
11 Business Strategy
Page 11
12 Agenda for today's discussion Key strategic priorities for our business Driving a more purpose-led and performance-oriented organization with stronger alignment across teams 1 2 Scaling core brands with sustained double-digit growth like Naprosyn progressing towards becoming a ₹100 cr+ brand 3 Building a stronger specialty and chronic portfolio with increasing contribution from new launches 4 Strengthening the API business with improved operational resilience and recovery post disruption 5 Expanding global presence with focused investments and deeper engagement with key international customers Embedding cost discipline and ESG-led practices to drive long-term sustainable operations 6
Page 12
13 Domestic Formulations (DF) Business: Overview & Strategy Business Overview Strategy Leading Textbook Brands Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace Diverse Portfolio Operating across mass, mass-specialty, and specialty segments. Innovation & Growth New launches in biosimilars, chronic, and specialty segments. Specialist Reach Strong presence across key specialties (Cardio, Diabetes, Urology, Nephrology, Rheumatology, Oncology) Product Portfolio Rejuvenation: Building chronic and specialty portfolios with new launches Strategic Brand Asset Building: Life cycle management through new line extensions, customer segments, & disease segments. Customer Coverage Deepening: Expanding field force & deploying digital solutions in targeted therapies Sales Force Effectiveness Augmentation: Enhancing competencies and productivity through targeted initiatives. Profitability Improvement: Controlling costs, improving efficiency, strengthening sales discipline, and focusing on profitable mix. 1 3 4 52 5 pillars of profitable domestic business growth
Page 13
14 Expand Footprint in Emerging and Select Markets: Grow presence in markets such as Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan, Thailand, and South Africa. Focus on Products with Competitive Advantage: Prioritize products requiring special manufacturing conditions (e.g., low RH/temperature), complex generics, and those with low competition International Formulations (IF) Business: Overview & Strategy Strategy Specialist Leadership Strong position in immunosuppressants, with Azathioprine as a flagship product. Build Immunosuppressant Portfolio: Expand leadership in immunosuppressants, anchored by flagship products like Azathioprine. 1 32 Global Reach Presence in regulated and emerging markets across Canada, UK, Germany, France, Australia, SE Asia, and Africa Trusted Partnerships Impeccable supply track record and enduring relationships with leading global generic players. Quality & Expansion Preferred partner for high- quality, process-oriented manufacturing; ongoing investments in plant upgrades and capacity expansion. 3 pillars of step-wise global business build up Business Overview
Page 14
15 State-of-the-Art Manufacturing: Operate EU/TGA-approved plant with enhanced capacity for quality and compliance. Niche Product Pipeline: Develop immunosuppressants, limited competition products, and support backward integration for IF/DF . APIs Business: Overview & Strategy Business Overview Strategy Niche API Focus High-value, low-volume APIs and mature, stable molecules. Global Presence Presence across key geographies: LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, and more. Strategic Integration Backward integration with International Formulations, strengthening supply chain resilience. Trusted Partnerships Enduring relationships with major pharma and leading generic companies. Market & Customer Expansion: Grow reach for existing products in new and established markets. 1 32 3 pillars of API growth
Page 15
16 Q1- FY27 Performance
Page 16
17 Robust Q1- 27 performance with 15.8% revenue growth and 17.0% PAT growth 17.0% PAT (excl. exceptional items) Q1 FY27 v/s Q1 FY26 15.8% Revenue from operations Q1 FY27 v/s Q1 FY26 17.9% EBITDA Q1 FY27 v/s Q1 FY26
Page 17
18 EBITDA & EBITDA MarginRevenue from Operations (All values in Rs. Crores) Q1 FY27 Financial Performance (Consolidated) : Revenue up by 15.8% with improved profitability values in circle are margins 168.9 195.7 Q1 FY26 Q1 FY27 +15.8% PBT & PBT Margin PAT & PAT Margin 40.7 48.0 Q1 FY26 Q1 FY27 +17.9% 24.1% 24.5% 35.4 41.5 Q1 FY26 Q1 FY27 +17.0% 21.0% 21.2% 26.3 30.8 Q1 FY26 Q1 FY27 +17.0% 15.6% 15.7%
Page 18
19 Q1 FY27: Business Segment -wise Performance Update Domestic Formulations contributed 68.3% to total sales in Q1 FY27 • Continue to deliver market beating growth • New products contribution improving consistently on account of new launches in specialty & chronic segments • Salesforce productivity consistently improving (currently >6.5 lakhs) • Business driven by 5 Pillar strategy API contributed 13.7% to total sales in Q1 FY27 • Growth impacted due to fire incident in one of the manufacturing blocks • Continuous thrust on new customer development • Business driven by 3 Pillar strategy International Formulations contributed 18.0% to total sales in Q1 FY27 • Focus on long-term business development activities including adding new products, customers and markets • Business driven by e Pillar strategy 19 Domestic Formulations (DF) International Formulations (IF) API 115.4 132.5 Q1 FY26 Q1 FY27 +14.8% All sales value in INR cr . 32.5 35.0 Q1 FY26 Q1 FY27 +7.7% 19.6 26.6 Q1 FY26 Q1 FY27 +35.6%
Page 19
20 Long term rating reaffirmed at A+ and outlook retained as stable Short term rating reaffirmed at A1 Improvements recorded in ICRA Rating- June’26 • Strong brands in the Indian Pharmaceutical Industry • Steady growth in top -line and improving operating margins • A robust capital structure and strong debt servicing indicators based on: o Healthy cash flows o Strong balance sheet o No debt-funded capital expenditure (capex) • Expansion of product portfolio and geographical presence augur well for growth prospects Factors contributing rating affirmation RPG Life Sciences ICRA Rating Reaffirmation: A+ rating continues
Page 20
21 Key milestones in Q1 FY27 Among the Top 5 Fastest Growing Companies in IPM1 in Q1 FY27 RPGLS enters coveted list of “T op 50 Pharma Company” in June’26 1. Indian pharma market 2. Source: Pharmarack MAT June 2026 Database Key highlights RPGLS has advanced IPM2 ranking from Rank 62 in Mar’25 to Rank 50 in June’262 1 2
Page 21
22 Our efforts gaining external recognition; 3 industry awards received in Q1 FY27 Awarded for “Excellence in Breakthrough Pharmaceutical Innovations” Awarded for deploying innovative sales force effectiveness measures like automation of secondary sales statements and league table scorecard for the field Awarded for “Best Use of AI in Sales Force Effectiveness” Gaining traction of select SFE and AI platforms built in FY26 Awarded the prestigious “T op Nephrology Company-2026” Awarded for delivering strong patient care through robust portfolio of high -quality medicines in kidney care space
Page 22
23 Journey Ahead
Page 23
24 RPGLS Journey Ahead: 7 strategic pillars of action Portfolio development and mega-brands building • Project underway to grow our immunosuppressant portfolio to 200+ crores • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio 1 • Focus on new geographies, new launch pipeline and enhancing manufacturing productivity • Focus on strengthening customer relationships and onboarding new high-value customers Growing our API business 2 • M&A Framework with criteria defined - target therapies, brands • Evaluation of multiple proposals underway to identify opportunities for growth synergy Mergers & Acquisitions 4 • Multiple digital initiatives designed to streamline front-end and backend operations • Initiatives focus on improving efficiency & compliance, reducing costs and growing topline Strong Digital Roadmap 3 • Org structure review & role/skill-gaps identification for strengthening • Talent development and talent acquisition across all key business and support functions Talent Transformation 7 State-of-art capacity plants • Rs 185+ crores capex infused since FY22 helped build modern plant with EU, TGA, PMDA, etc. approval • Evaluation ongoing of varied opportunities for improving manufacturing productivity 6 • Focused new product pipeline; lab modernization and org expansion complete • Strategy to evaluate and expand into adjacencies in RPGLS strength therapies New products across segments, new therapies 5
Page 24
25 THANK YOU